Merck/Bayer set to challenge Novartis in heart failure after...

Merck & Co and Bayer’s heart failure drug vericiguat has hit its target in a phase 3 trial, vindicating a decision by the big US pharma to buy into the project for $1 billion.<

Janssen taps wearable tech in Invokana heart failure trial

Boehringer, Lilly start acute heart failure trial with Jardi...

FDA approves AZ's Farxiga in new heart failure prevention us...

The FDA has approved AstraZeneca’s diabetes drug Farxiga to reduce the chances of hospitalisations for heart failure in adults with type 2 diabetes and other cardiovascular risks.<

AZ's Farxiga gets FDA Fast Track for heart failure

The FDA has fast-tracked AstraZeneca’s Farxiga (dapagliflozin) as a treatment to reduce risk of cardiovascular death, or worsening of heart failure, in adults with reduced or preserved ejec

Despite trial miss, Novartis still believes in Entresto for ...